NovoCure Limited (NVCR)
Automate Your Wheel Strategy on NVCR
With Tiblio's Option Bot, you can configure your own wheel strategy including NVCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVCR
- Rev/Share 5.6375
- Book/Share 3.2821
- PB 5.1186
- Debt/Equity 1.9249
- CurrentRatio 1.4655
- ROIC -0.1983
- MktCap 1872964800.0
- FreeCF/Share -0.6542
- PFCF -25.9622
- PE -11.2844
- Debt/Assets 0.5579
- DivYield 0
- ROE -0.4546
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVCR | H.C. Wainwright | Neutral | Buy | $24 | $30 | Oct. 16, 2024 |
News
What Makes NovoCure (NVCR) a New Buy Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
Read More
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for NovoCure (NVCR) points to a 105.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Why NovoCure Stock Skyrocketed This Week
Published: April 25, 2025 by: The Motley Fool
Sentiment: Positive
Shares of NovoCure (NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m.
Read More
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
Published: April 24, 2025 by: Benzinga
Sentiment: Negative
NovoCure Ltd NVCR reported a first-quarter 2025 loss of 31 cents, down from the 36-cent loss reported a year ago, beating the consensus loss of 46 cents.
Read More
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
NovoCure Surpasses Q1 Expectations
Published: April 24, 2025 by: The Motley Fool
Sentiment: Positive
NovoCure (NVCR 7.15%), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street's estimate of $146 million.
Read More
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Negative
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.36 per share a year ago.
Read More
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Published: March 04, 2025 by: The Motley Fool
Sentiment: Positive
Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Read More
NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Positive
NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs will rise in 2025.
Read More
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
About NovoCure Limited (NVCR)
- IPO Date 2015-10-01
- Website https://www.novocure.com
- Industry Medical - Instruments & Supplies
- CEO Ms. Ashley Cordova
- Employees 1488